Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tevogen Bio Holdings Inc (TVGN)

Tevogen Bio Holdings Inc (TVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Tevogen Bio Reports Significant Reduction in Net Loss and Dramatic Improvement in Financial Position for Q3 2024

Tevogen Bio reported a reduced net loss and improved financial position, eliminating most liabilities and retaining substantial equity among officers.Quiver AI SummaryTevogen Bio announced its financial...

TVGN : 1.3600 (+2.26%)
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio Highlights Sustainable Growth and Strategic Financing in Upcoming Quarterly Financial Report

Tevogen Bio reports progress in developing immunotherapy, maintaining low expenditures and focusing on sustainable growth while preserving shareholder value.Quiver AI SummaryTevogen Bio, a clinical-stage...

TVGN : 1.3600 (+2.26%)
UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)
Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

TVGNW : 0.0583 (-3.16%)
TVGN : 1.3600 (+2.26%)

Barchart Exclusives

Is C3.ai Stock a Buy After the Microsoft Deal?
The expansion of C3.ai’s partner ecosystem has worked in favor of the company by enabling it to close increased number of agreements and remains a significant growth driver. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar